Caliway Advances CBL-514 With FDA-Cleared Phase 2 Trial And Phase 3 Enrollment

Caliway Biopharmaceuticals (6919.TW) said the U.S. FDA cleared its Investigational New Drug (IND) application for CBL-0201WR, enabling a Phase 2 trial of CBL-514 in combination with tirzepatide for abdominal subcutaneous fat reduction in overweight or obese patients. The FDA clearance is a key regulatory milestone that reduces development friction for the program. Overall, it should be supportive for the stock’s perceived pipeline progress, though impact is likely limited until clinical readouts emerge.